MDLN SEC Filings

Medline Inc. (MDLN) filed an 8-K on July 9, 2026, to report the upcoming retirement of its Chief Operating Officer (COO), Stephen L. Miller, effective August 30, 2026. The company cited health-related reasons for Mr. Miller's departure. Medline Inc. has initiated a search process to identify and appoint a successor to this key executive role. This announcement marks a significant change in the company's senior leadership. Investors should monitor the selection of the new COO, as this individual will play a crucial role in executing Medline's operational strategies and future growth initiatives. The transition timeline allows for a structured handover, but the market will likely be keen to understand the company's plans for ensuring operational continuity and a smooth leadership transition during this period.

Medline Inc. (MDLN) filed an 8-K on June 12, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. The primary outcomes include the election of all 12 director nominees, overwhelming approval of the Company's executive compensation on an advisory basis, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. Importantly, stockholders also approved holding advisory votes on executive compensation annually.

Medline Inc. (MDLN) has filed an 8-K report detailing significant refinancing transactions executed on May 28, 2026. The company successfully issued $2.0 billion in aggregate principal amount of new senior secured notes, comprising $1.25 billion of 5.000% notes due 2031 and $750 million of 5.250% notes due 2033. These proceeds, along with new term loan borrowings and cash on hand, were utilized to repay existing debt, including a senior secured term loan due 2028 and a portion of its 2030 term loan facility, as well as to redeem a portion of its 2029 senior secured notes. This strategic move aims to extend debt maturities, potentially lower interest costs, and improve its overall debt structure. In parallel, Medline also amended its credit agreement to refinance its existing senior secured term loan facility due 2030 with a new approximately $2.75 billion senior secured dollar-denominated term loan facility due 2033. The company also announced a public offering of Class A common stock by certain selling stockholders, raising approximately $2.68 billion. While the debt transactions focus on capital structure optimization, the equity offering reflects potential liquidity events for major shareholders.

Medline Inc. (MDLN) filed an 8-K on May 6, 2026, to report its financial results for the first quarter ended March 28, 2026. The filing primarily directs investors to an accompanying earnings press release (Exhibit 99.1) for detailed financial performance and operational updates. Investors should refer to this press release for specific figures on revenue, profitability, and any forward-looking statements or management commentary. While the 8-K itself does not contain the financial data, its purpose is to officially announce the release of these results, making them publicly available. The information provided is considered 'furnished' rather than 'filed,' which has implications under SEC regulations regarding liability for forward-looking statements. Investors seeking a comprehensive understanding of Medline's current financial health and outlook should carefully review the press release referenced in this filing.

Medline Inc. reported solid revenue growth of 10.7% for the quarter ended March 28, 2026, reaching $7.35 billion, driven primarily by increased volumes across its U.S. operations, particularly within the acute care segment. Despite this top-line expansion, net income saw a decline of 25.8% to $239 million, largely due to a significant increase in Cost of Goods Sold (up 14.3%) and Selling, General, and Administrative (SG&A) expenses (up 14.8%). Higher import costs related to tariffs and increased compensation and distribution expenses were key drivers for the rise in operating costs. The company also experienced a substantial decrease in interest expense, down 35.2% to $136 million, following the repayment of significant debt portions using IPO proceeds in the prior year, which positively impacted profitability. The balance sheet remains strong with $2.24 billion in cash and cash equivalents and $946 million in available liquidity under its revolving credit facility. The company continues to manage its financial obligations, with a total indebtedness of $12.76 billion as of the quarter's end.

Medline Inc. (MDLN) reported strong performance for the fiscal year ended December 31, 2025, with net sales reaching $28.4 billion, a 11.5% increase year-over-year. This growth was primarily driven by increased volumes across its Prime Vendor relationships and its Medline Brand products. The company's strategy of leveraging its Prime Vendor model, differentiated distribution network, and robust commercial platform continues to yield positive results, evidenced by over 1,600 Prime Vendor relationships contributing significantly to revenue. Despite an 11.5% increase in net sales, net income saw a slight decrease of 3.6% to $1.16 billion, impacted by higher cost of goods sold and increased selling, general, and administrative expenses. Notably, tariffs had a $290 million adverse impact on income before taxes. The company's Medline Brand segment showed solid net sales growth of 9.6%, while the Supply Chain Solutions segment experienced a notable 13.2% increase in net sales. Medline Inc. also successfully completed its Initial Public Offering (IPO) in December 2025, generating substantial proceeds that were used to repay debt and for general corporate purposes.

Medline Inc. (MDLN) has filed a Form 8-K on February 25, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. While the 8-K itself does not contain the detailed financial figures, it formally announces that Medline has issued an earnings press release containing this information, which is furnished as Exhibit 99.1 to this filing. Investors should refer to the press release (Exhibit 99.1) for specific details on Medline's performance. This filing serves as the official notification of the release of these results, indicating that key metrics such as revenue, profitability, and any significant year-over-year changes are now publicly available through the attached press release. The company is providing this update in compliance with SEC regulations regarding the disclosure of material financial information.

Medline Inc. (MDLN) filed an 8-K report on December 22, 2025, detailing key events surrounding its initial public offering (IPO) on December 16, 2025. The filing primarily concerns the execution of material definitive agreements essential for its transition to a publicly traded company. These agreements establish the operational and governance framework post-IPO, including the Medline Holdings Limited Partnership Agreement, a Tax Receivable Agreement, an Exchange Agreement, and a Registration Rights Agreement. Furthermore, the report announces the appointment of Todd M. Bluedorn to the Board of Directors and his role on the Audit Committee, including an RSU award. The company also formally adopted its 2025 Omnibus Incentive Plan and 2025 Employee Stock Purchase Plan. The amended Certificate of Incorporation and Bylaws, effective December 16, 2025, outline the authorized capital stock structure. Notably, the company successfully completed its IPO, issuing 248,439,654 shares of Class A Common Stock at $29.00 per share, generating significant proceeds used for debt repayment and strategic acquisitions of common units from pre-IPO owners.